Biocept Announces Full Commercial Launch of CNSide Cerebrospinal Fluid Assay to Address Unmet Needs for Patients with Metastatic Brain Cancer - Seite 2

Nachrichtenquelle: Business Wire (engl.)
21.04.2021, 14:17  |  146   |   |   

“The full sales force launch of our CSF assay, along with new branding, is an exciting next step toward our goal of establishing CNSide as a new standard-of-care diagnostic test for cerebrospinal fluid,” said Michael Nall, Biocept’s President and CEO. “Initial acceptance by neuro-oncology early-adopters has been highly encouraging as physicians from nearly two dozen leading academic institutions have ordered CNSide—with many becoming repeat users. This represents a significant market opportunity that we estimate at more than $1 billion annually in the United States for breast and lung cancers that have metastasized to the central nervous system.”

In 2020, Biocept presented highly favorable results from pilot studies with the assay at three major scientific meetings.1-3 The studies showed that in approximately 80% of the cases of suspected CNS involvement, tumor cells were detected using the CNSide assay, compared with about 50% of cases examined by CSF cytology. The assay is currently validated to identify metastatic cancers originating in the lung and breast. Biocept plans to expand its CSF testing menu for additional tumor types and biomarkers in the future.

A recent webinar hosted by Biocept featured leading neuro-oncologists discussing the use of the CNSide assay for diagnosing and managing tumors that have metastasized to the CNS. The webinar can be viewed here.

About Biocept

Biocept, Inc., develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept’s patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic. For more information, visit Follow Biocept on Facebook, LinkedIn and Twitter.

Seite 2 von 3
Biocept Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf


0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren



Biocept Announces Full Commercial Launch of CNSide Cerebrospinal Fluid Assay to Address Unmet Needs for Patients with Metastatic Brain Cancer - Seite 2 Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, has announced the full commercial launch of CNSide, its cerebrospinal fluid (CSF) assay designed to better detect and manage treatment of …


Nachrichten des Autors